G.ST Antivirals

Our CEO Guido Gualdoni, MD, PhD is meeting partners at the LSX World Congress in London today and tomorrow- reach out if you are around!

🎉 Exciting news from G.ST Antivirals continue! We're thrilled to announce that our Chief Scientific Officer, Anna-Dorothea Gorki, has been nominated as a Voice of a New Era of Leaders by the female factor. This nomination reflects the innovative spirit and leadership that Anna-Dorothea brings to our team and the biotech community. Congratulations, Thea! We are immensely proud of your well-deserved recognition. #Leadership #Innovation #Biotech #FemaleFactor #TeamPride https://lnkd.in/dy5zyYBb

We are excited to share two major announcements today 🎉 🌟 Please join us in welcoming Ronald Bruce Turner, our new Chief Medical Officer, to the team! Ron brings a wealth of experience in the field of respiratory viral infections and is a globally recognized Key Opinion Leader. He is a former Professor of Pediatric Infectious Diseases at the University of Virginia Medical School, has published over 140 articles, reviews and book chapters and advised numerous companies researching respiratory viral infections. Ron will oversee our current clinical trial and drive further clinical development at G.ST Antivirals. We are very much looking forward to working together! 🧪 We have started our Phase II clinical trial with 2-DG: Our lead asset, a broad-spectrum antiviral nasal spray containing 2-Deoxy-D-glucose (2-DG) has entered a Phase 2 study and the first subject was dosed on April 2nd, 2024. The randomized, double-blind, placebo-controlled Phase II rhinovirus-challenge study is conducted at the Centre for Human Drug Research in Leiden, the Netherlands. We are excited to advance our clinical development and bring our promising broad-spectrum antivirals closer to patients in need 🩺 Read the full press release here: https://lnkd.in/d7ghM7Zn

🌟 Big News from Our Team! 🌟 We're very proud as our Chief Scientific Officer, Anna-Dorothea Gorki, is awarded the State Prize by the Federal Minister of Science Dr. Martin Polaschek for her pioneering work in developing in vitro lung models. A huge congratulations to Anna-Dorothea- Here’s to many more achievements! #Biotech #Innovation #TeamPride

Another piece of data showing that despite progress in RSV infections, too many infants will continue to suffer from life-threatening respiratory infections by other viruses. An additional motivation for us at G.ST Antivirals to do everything we can to deliver antiviral options for the most vulnerable among us! https://lnkd.in/dgWyaAaV

We are thrilled to announce two major milestones for G.ST Antivirals today! 🚀 🎉 Positive results from our Phase I trial: Intranasal administration of our lead product, a nasal spray containing 2-Deoxy-D-Glucose (2-DG), was safe, well tolerated and did not lead to any serious adverse events. The compound tackles rhinoviruses, which cause the #commoncold and more severe respiratory diseases in vulnerable individuals, and other important agents such as #coronaviruses. This is a big step forward in our mission to bring broad-spectrum antivirals against upper respiratory infections to patients, using our innovative, host cell-based strategy. 💰 Successful #financing: We are delighted to share that we have raised over EUR 6 million for the Phase II trial, which is set to start in the first half of 2024. The funds comprise a EUR 4 million Series A round led by xista science ventures with participation from the Lansdowne Investment Company, an investment vehicle managed by Lansdowne Partners Austria GmbH, as well as a funding commitment of EUR 2.2 million from the Life Sciences Programme of the FFG Österreichische Forschungsförderungsgesellschaft mbH A big thank you to our supporters and our incredible team who make this journey possible! 🙌 Read the full press release here: https://lnkd.in/dx9qHc_2 #antiviral #rhinovirus #Virology #BiotechInnovation #PhaseI

Meet our CEO Guido Gualdoni at next week's Startup-desk! https://lnkd.in/dEQE7ni3

We've had a fantastic year so far at G.ST Antivirals 🤩 ! We completed the phase 1 study on our first clinical stage compound, launched two pre-clinical development programs and got selected to participate in this year's EIT Health Catapult program! Our unique way of combating viral diseases is well on track to make a difference in patients' lives very soon! Intrigued? Listed to the company's executives explain our mission in our newest video 🚀

Now also available online- read about the "Viennese virus killers" in Forbes DA! https://lnkd.in/d4AiTyKe

At G.ST Antivirals we are not only super fast when it comes to drug development- we are also pretty quick at running 🏃♂️ 🏃♀️ 🏅 It was a blast to participate in this year's Vienna Night Run- we are looking forward to next year's edition!